Abstract
Introduction: The aim of this study was to explore the differences in status epilepticus (SE) management among pediatric neurology, emergency medicine, and intensive care specialists in Turkey. Methods: A 22-item questionnaire regarding first-, second-, and third-line management strategies of SE including demographic characteristics and common etiologies according to the specialty of participants was mailed to 370 specialists working in Turkey. Results: A total of 334 participants (response rate 90%) comprising 136 pediatric neurologists, 102 pediatric emergency medicine specialists, and 96 pediatric intensive care specialists completed the survey. While intensive care specialists frequently managed SE due to metabolic and autoimmune reasons, the most common etiologies encountered by emergency medicine specialists were epilepsy and infections. More than half of the intensive care specialists (64.6%) reported using non-BZD antiseizure medications in the 5th minute of the seizure. Most of the neurologists (76.4%) preferred to administer intravenous (IV) levetiracetam infusion as a second-line agent. About half of intensive care specialists and neurologists tried immunomodulatory therapies in super-refractory SE. Intensive care and emergency medicine specialists were less likely to favor ketogenic diet and pyridoxine therapy for the treatment of super-refractory SE. The rate of requesting EEG monitoring to recognize nonconvulsive SE (NCSE) was found to be very low except for neurologists. Conclusion: There was no consensus among neurologists, intensive care specialists, and emergency medicine specialists in the management of SE in Turkey. Familiarity with particular antiseizure medications and the etiologies they manage seem to be the most important factors influencing the attitudes.
Journal Section:
Clinical Neurology: Research Article
References
1.
Trinka
E
, Cock
H
, Hesdorffer
D
, Rossetti
AO
, Scheffer
IE
, Shinnar
S
. A definition and classification of status epilepticus: report of the ILAE task force on classification of status epilepticus
. Epilepsia
. 2015
;56
(10
):1515
–23
.2.
Gurcharran
K
, Grinspan
ZM
. The burden of pediatric status epilepticus: epidemiology, morbidity, mortality, and costs
. Seizure
. 2019 May
68
3
8
.3.
Novorol
CL
, Chin
RF
, Scott
RC
. Outcome of convulsive status epilepticus: a review
. Arch Dis Child
. 2007
;92
(11
):948
–51
.4.
Eriksson
K
, Metsaranta
P
, Huhtala
H
, Auvinen
A
, Kuusela
AL
, Koivikko
M
. Treatment delay and the risk of prolonged status epilepticus
. Neurology
. 2005
;65
(8
):1316
–8
.5.
Messahel
S
, Bracken
L
, Appleton
R
. Optimal management of status epilepticus in children in the emergency setting: a review of recent advances
. Open Access Emerg Med
. 2022
;14
:491
–506
.6.
Zimmern
V
, Korff
C
. Status epilepticus in children
. J Clin Neurophysiol
. 2020
;37
(5
):429
–33
.7.
Abend
NS
, Loddenkemper
T
. Pediatric status epilepticus management
. Curr Opin Pediatr
. 2014
;26
(6
):668
–74
.8.
Vasquez
A
, Farias-Moeller
R
, Tatum
W
. Pediatric refractory and super-refractory status epilepticus
. Seizure
. 2019
;68
:62
–71
.9.
Lawton
B
, Davis
T
, Goldstein
H
, Tagg
A
. An update in the initial management of paediatric status epilepticus
. Curr Opin Pediatr
. 2018
;30
(3
):359
–63
.10.
Barcia Aguilar
C
, Sánchez Fernández
I
, Loddenkemper
T
. Status epilepticus-work-up and management in children
. Semin Neurol
. 2020
;40
(6
):661
–74
.11.
Crawshaw
AA
, Cock
HR
. Medical management of status epilepticus: emergency room to intensive care unit
. Seizure
. 2020
;75
:145
–52
.12.
Glauser
T
, Shinnar
S
, Gloss
D
, Alldredge
B
, Arya
R
, Bainbridge
J
. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society
. Epilepsy Curr
. 2016
;16
(1
):48
–61
.13.
Capovilla
G
, Beccaria
F
, Beghi
E
, Minicucci
F
, Sartori
S
, Vecchi
M
. Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League against Epilepsy
. Epilepsia
. 2013
54
Suppl 7
23
34
.14.
Zhao
ZY
, Wang
HY
, Wen
B
, Yang
ZB
, Feng
K
, Fan
JC
. A comparison of midazolam, lorazepam, and diazepam for the treatment of status epilepticus in children: a network meta-analysis
. J Child Neurol
. 2016
;31
(9
):1093
–107
.15.
Brigo
F
, Nardone
R
, Tezzon
F
, Trinka
E
. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis
. Epilepsy Behav
. 2015
;49
:325
–36
.16.
Cohen
NT
, Chamberlain
JM
, Gaillard
WD
. Timing and selection of first antiseizure medication in patients with pediatric status epilepticus
. Epilepsy Res
. 2019
;149
:21
–5
.17.
Lewena
S
, Pennington
V
, Acworth
J
, Thornton
S
, Ngo
P
, McIntyre
S
. Emergency management of pediatric convulsive status epilepticus: a multicenter study of 542 patients
. Pediatr Emerg Care
. 2009
;25
(2
):83
–7
.18.
Dalziel
SR
, Borland
ML
, Furyk
J
, Bonisch
M
, Neutze
J
, Donath
S
. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial
. Lancet
. 2019
;393
(10186
):2135
–45
.19.
Lyttle
MD
, Rainford
NEA
, Gamble
C
, Messahel
S
, Humphreys
A
, Hickey
H
. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
. Lancet
. 2019
;393
(10186
):2125
–34
.20.
Riviello
JJ
Jr, Claassen
J
, LaRoche
S
, Sperling
MR
, Alldredge
B
, Bleck
TP
. Treatment of status epilepticus: an international survey of experts
. Neurocrit Care
. 2013
;18
(2
):193
–200
.21.
Chamberlain
JM
, Kapur
J
, Shinnar
S
, Elm
J
, Holsti
M
, Babcock
L
. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial [published correction appears in Lancet
. Lancet
. 2020
;395
(10231
):1217
–24
.22.
Min
L
, Chunyan
W
, Biaoxue
R
. Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies
. BMC Pediatr
. 2020
;20
(1
):97
.23.
Star
K
, Edwards
IR
, Choonara
I
. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase
. PLoS One
. 2014
;9
(10
):e108970
.24.
Kravljanac
R
, Djuric
M
, Jankovic
B
, Pekmezovic
T
. Etiology, clinical course and response to the treatment of status epilepticus in children: a 16-year single-center experience based on 602 episodes of status epilepticus
. Eur J Paediatr Neurol
. 2015
;19
(5
):584
–90
.25.
Vossler
DG
, Bainbridge
JL
, Boggs
JG
, Novotny
EJ
, Loddenkemper
T
, Faught
E
. Treatment of refractory convulsive status epilepticus: a comprehensive review by the American epilepsy society treatments committee
. Epilepsy Curr
. 2020
;20
(5
):245
–64
.26.
Qadir
W
, Wani
KA
, Bhat
BA
. Sociodemographic profile, semiology, and etiology of patients with status epilepticus: a study from a tertiary care hospital in north India
. J Neurosci Rural Pract
. 2018
;9
(4
):487
–91
.27.
Cobo
NH
, Sankar
R
, Murata
KK
, Sewak
SL
, Kezele
MA
, Matsumoto
JH
. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units
. J Child Neurol
. 2015
;30
(2
):259
–66
.28.
Ferlisi
M
, Shorvon
S
. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy
. Brain
. 2012
135
Pt 8
2314
28
.29.
Dubey
D
, Pittock
SJ
, Kelly
CR
, McKeon
A
, Lopez-Chiriboga
AS
, Lennon
VA
. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
. Ann Neurol
. 2018
;83
(1
):166
–77
.30.
Arayakarnkul
P
, Chomtho
K
. Treatment options in pediatric super-refractory status epilepticus
. Brain Dev
. 2019
;41
(4
):359
–66
.31.
Meletti
S
, Monti
G
, Mirandola
L
, Vaudano
AE
, Giovannini
G
. Neuroimaging of status epilepticus
. Epilepsia
. 2018
59
Suppl 2
113
9
.32.
Mendes
A
, Sampaio
L
. Brain magnetic resonance in status epilepticus: a focused review
. Seizure
. 2016
;38
:63
–7
.33.
Payne
ET
, Zhao
XY
, Frndova
H
, McBain
K
, Sharma
R
, Hutchison
JS
. Seizure burden is independently associated with short term outcome in critically ill children
. Brain
. 2014
137
Pt 5
1429
38
.34.
Abend
NS
, Arndt
DH
, Carpenter
JL
, Chapman
KE
, Cornett
KM
, Gallentine
WB
. Electrographic seizures in pediatric ICU patients: cohort study of risk factors and mortality
. Neurology
. 2013
;81
(4
):383
–91
.35.
Sansevere
AJ
, Hahn
CD
, Abend
NS
. Conventional and quantitative EEG in status epilepticus
. Seizure
. 2019
;68
:38
–45
.36.
Liukkonen
E
, Kantola-Sorsa
E
, Paetau
R
, Gaily
E
, Peltola
M
, Granström
ML
. Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome
. Epilepsia
. 2010
;51
(10
):2023
–32
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
